Friday, December 17, 2021

In a trial, Pfizer-BioNTech’s low-dose shot did not provoke an adequate immune response in 2- to 5-year-olds.

Calling the vaccine a “three-dose series,” the company now plans to test three doses of its vaccine in children ages six months to 17 years.

from NYT > Top Stories https://ift.tt/33FLKXN
at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

D.O.J. Seeks to Halt Pollution Lawsuit Against Elon Musk’s Data Center

The department cited national security concerns, saying Elon Musk’s company had played a crucial role in the Iran war. It also argued it has...